Jodek Sodu Na131i Polatom (Sodium Iodide (131i))

After oral administration, sodium iodide is actively transported into thyroid cells via the sodium‑iodide symporter. The I‑131 isotope emits beta particles that destroy thyroid tissue and gamma photons that can be detected with a scanner, enabling imaging and therapeutic ablation.

The prescribed dose is determined by the treating physician based on the specific indication, patient weight, thyroid function, and radiation safety considerations. Dosing regimens are individualized and should follow local regulatory guidelines.

Use during pregnancy is generally avoided because the radioactive iodine can affect the fetal thyroid. Breastfeeding mothers should discontinue the medication and stop nursing until the radioactivity has cleared, as recommended by a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑radioactive antithyroid drugs, sodium iodide (Na131I) offers a single‑dose or short‑course option that directly ablates thyroid tissue, often reducing the need for long‑term medication. It differs from other radioactive iodine products mainly in isotopic purity and regulatory status.

Store the product below 25 °C in its original packaging, protecting it from moisture and direct sunlight. Ensure the container remains sealed until use and handle with standard radiation safety precautions as outlined in the product labeling.

The medication is taken orally, usually as a single dose or a short series of doses, depending on the clinical indication. Patients should follow the prescribing physician’s instructions regarding fasting status and timing relative to other medications.

Serious risks include severe hypothyroidism requiring lifelong hormone replacement, bone‑marrow suppression leading to low blood counts, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these events, especially after high‑dose therapy.

Contraindications include patients with known hypersensitivity to iodine or radioactive iodine, pregnant women unless absolutely necessary, and individuals with uncontrolled thyroid storm. Patients with severe renal impairment should also be evaluated carefully before use.